Introduction
Current treatment of patients with systemic lupus erythematosus (SLE) is based on drugs that suppress the immune system nonspecifically. Although this approach has led to a dramatic reduction of lupusrelated mortality, it is also a fact that aggressive and long-term immunosuppression causes serious adverse effects, which frequently outweigh its intended benefits. In SLE, where the disruption of immune tolerance is believed to be at the center of the disease pathogenesis, such practice poses an additional consideration: there is evidence that immunosuppression can hinder the natural mechanisms of tolerance to autoantigens. 1, 2 It is thus well understood that more specific and less toxic treatments are needed to successfully confront this devastating disease.
Use of autoantigen defined peptides
Whereas in normal individuals potentially pathogenic autoreactive lymphocytes are strictly regulated, 3 in SLE, breakdown of tolerance permits the survival, activation and outgrowth of autoreactive B and T cells which, either through direct infiltration or their secreted products, mediate inflammation and tissue injury. 4 In this context, it has been proposed that administration of peptides that represent 'pathogenic' autoantigens would specifically target autoreactive B and/or T cells and could restore tolerance of these cells towards the primary immunogen that drives the autoimmune response. Apparently, the design of such peptides requires the identification of pathogenic autoantigendefined epitopes. Based on the ability to stimulate autoreactive CD4 þ cells ex vivo or to accelerate disease in preautoimmune mice, several groups have recognized more than 60 distinct putative autoantigendefined epitopes located in nucleosome core histones, 5 ribonucleoproteins, 6, 7 and immunoglobulin variable regions. 8 -10 To verify the initial hypothesis, preautoimmune as well as diseased lupus mice were vaccinated with peptides representing different antigens. Several studies have shown that in preautoimmune mice, autoAb production and tissue injury was delayed and that survival was prolonged. 8,11 -15 Nevertheless, because prophylactic treatment cannot be applied in humans, the efficacy of this approach in diseased animals possesses greater interest. Few studies were successful in mice with overt clinical disease. Administration of the H4 peptide 16-39 to SNF1 mice; 11 of a consensus peptide derived from the VH region of several anti-DNA antibodies (pCONs) to BW mice; 16 and of a peptide derived from the sequence of the complementary determining region 3 (CDR3) of an anti-DNA antibody that expresses the 16/6 Id delivered to BW mice, 17 all resulted in improvement of established disease. In this issue, Kalsi et al. present experiments which suggest that selective anti-DNA VH region-defined peptides may elicit altered cytokine response from peripheral blood mononuclear cells from SLE patients. 10 The recorded changes in cytokine production are small and need to be confirmed in more stringent studies. Yet, the data indicate that peptide immunization can be considered for therapeutic purposes in humans as it has been tried in mice. Although limited in number, the studies in autoimmune mice represent a major advance towards the restoration of autoantigen-specific tolerance in SLE. However, a better understanding of the mechanisms involved is needed before such strategies can be applied to patients. Since numerous antigenic determinants have been identified in both humans and mice with lupus, someone can argue that administration of a single autoantigen-defined peptide cannot modulate efficiently the whole gamut of the autoimmune response that involves multiple autoantigens. Tolerance spreading proposed by Datta and colleagues represent an attractive explanation. 5, 11 It remains though to be determined whether a single autoantigen may indeed reliably initiate an autoimmune response against multiple antigens. Alternatively, multiple autoantigen-derived peptides can be used for the treatment of systemic autoimmune diseases such as lupus. In addition, studies mentioned above as well as studies engaging other spontaneous autoimmune animal models have demonstrated that several other factors interfere with the generation of a tolerogenic response (e.g., dose, route of administration, disease stage) as well as peptide stability.
Modulation of costimulation
Another approach to restore immune tolerance in SLE is the blockade of costimulation. Regulatory defect in the expression of CD40 ligand (CD40L) in patients with SLE has been established and is believed to result in the delivery of abnormal costimulatory signals that sustain the production of pathogenic antibodies. 18 Interruption of this pathogenic process in lupus mice treated with anti-CD40LmAb, resulted in prevention of lupus manifestations. 19 Unfortunately, to date, anti-CD40L treatment in human lupus did not produce the anticipated results. 20 Blockade of another costimulatory pathway following administration of the fusion protein CTLA4Ig, a competitive antagonist of CD28 by blocking the engagement of B7 molecules, leads to decrease in autoantibody production and delay in disease occurrence in NZB/W lupus-prone mice. 21 The efficacy of CTLA4Ig in the induction and maintenance of remission of nephritis in patients with SLE is currently under investigation. Although these strategies still hold significant promise, it should be noted that they lack the desirable specificity. That is, elimination of the costimulatory signal presumably affects responses to both self and foreign antigens and thus leading to generalized immunosuppression.
The development of autoantibody ligands
Assuming that autoreactive B cells express surface immunoglobulin that recognizes autoantigen, efforts have been invested in the development of reagents that would be recognized by B cell surface autoantibody. The first effort obviously focused on the development of small DNA fragments linked to a backbone that would be recognized and bound by anti-DNA abs. LJP 394 (abetimus sodium), which consists of four 20 base pair dsDNA oligonucleotides conjugated to a triethylene glycol plate, is able to crosslink anti-dsDNA Abs both in solution as well as on the surface of B cells. 22 This compound was designed based on findings where crosslinking of surface immunoglobulin, with a construct containing oligovalent B cell epitopes on a nonimmunogenic context can tolerize the target B cells if the construct lacks T cell epitopes. Accordingly, LPJ 394 can specifically target and tolerize pathologic B cells producing anti-dsDNA Abs through a single signal anergy/apoptosis mechanism. Administration of LPJ 394 was shown to decrease anti-dsDNA Abs levels in both lupus mice and patients with SLE. 23 Recently, LPJ 394 was examined for the treatment and the prevention of renal flares in 230 patients with SLE in a 76-week period study. 24 Significant decrease in the number of renal flares was recorded in patients demonstrating high affinity antibodies to the DNA epitopes of the drug. In these patients, treatment with LPJ 394 also led to the reduction of concomitant use of other immunosuppressive interventions. In addition, clinical benefit appeared to parallel the decrease of anti-dsDNA Abs titers. Although this set of data is promising, it appears that administration of LPJ 394 should be limited to patients with high affinity anti-DNA Abs. In addition this approach addresses only the possible pathogenic role of anti-dsDNA Abs and respective B cells in the expression of the disease. Findings in lupus mice and patients as well as our experience derived from the administration of the B cell depleting anti-CD20 Ab, support the notion that B cells cannot solely account for the disease as well as that anti-dsDNA Abs levels are frequently irrelevant to disease activity. Currently, an ongoing multinational, prospective, randomized controlled study investigates whether treatment with LPJ 394 delays the appearance of renal flares in patients with a history of renal disease and high affinity Abs and a similar approach has been initiated to reestablish tolerance in patients with antiphospholipid antibody syndrome.
Interference with B cell stimulating factors
Escape from apoptosis is a potential mechanism that may lead to the expansion of autoreactive T and/or B cells in SLE. Inhibition of such mechanisms can restore immune tolerance. The recently discovered B lymphocyte stimulator (Blys), is a type II membrane protein that exists in both membrane-bound and soluble forms and is required for the development of B lymphocytes into mature plasma B cells. 25 Blys, primarily produced by monocytes/macrophages and dendritic cells, is believed to render an anti-apoptotic signal to B cells. BLyS-transgenic mice develop severe B cell hyperplasia and autoimmune lupus-like disease characterized by the presence of autoantibody against nuclear antigens as well as immune complex deposits in the kidney. 26 In patients with SLE, Blys was found to be elevated and to correlate with disease activity. 27, 28 A recombinant, fully human IgG1 anti-Blys monoclonal Ab has been designed (Lymphostat-B) while preliminary results from its administration in lupus animal models show increased survival of treated animals. A phase I short term clinical trial with SLE patients demonstrated that the drug is well tolerated and that it is effective in lowering the number of CD20 þ B cells. 29 At present, a phase II clinical trial examines the therapeutic efficacy of this regimen.
Use of antigen presenting cells to restore tolerance
It has been shown that when B cells present antigen in the context of Ig, an-antigen specific tolerance is successfully established. 30 Accordingly, conjugation of a putative autoantigen to IgG can restore tolerance to autoantigen and reverse autoimmune pathology. Indeed, conjugation of uveitogenic interphotoreceptor retinoid-binding protein, the putative antigen for uveitis, to IgG by genetic engineering, transfer of the construct into syngeneic B cells and then into properly immunized animals, prevents and even reverses uveitis. 31 In the case of SLE, multiple putative autoantigen can be inserted in to the IgG vector with the expectation that one or some of them will be able to re-establish tolerance.
The exact mechanism(s) that promote the loss of T and B cell tolerance in SLE are not well understood. Because autoantigen epitopes are present in both normal individuals and patients with SLE, it appears that autoreactivity is a result of inherent functional defects of lupus cells. SLE lymphocytes display distinct biochemical abnormalities that lead to lower activation threshold to antigen and probably to autoantigen as well. 32 Detailed definition of the molecular events that orchestrate the autoreactive SLE lymphocyte behavior would certainly provide more specific therapeutic targets. The discussion presented herein takes into account only the role of lymphocytes into the tolerizing/autoreactive process. Nevertheless, accumulated evidence exists showing that organ injury, the main consideration when treating SLE patients, is dictated by additional local factors. The importance of local mechanisms is further supported by the fact quite frequently, the clinical course of the disease is in difference with the autoimmune manifestations of the disease. 33, 34 The future should hold approaches that address both autoimmunity and organ injury.
